Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions
Effects of other drugs on Lysergide
7 evidence topics · 7 sources
Paroxetine (selective serotonin reuptake inhibitor and strong CYP2D6 inhibitor)
“The present study investigated the acute response to single doses of LSD (100 μg) after daily administration of paroxetine (10 mg for 7 days, followed by 20 mg for 35 days) or placebo (42 days) using a randomized, double‐blind, cross‐over design in 23 healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Paroxetine did not alter pleasant subjective effects of LSD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The strong cytochrome P450 2D6 (CYP2D6) inhibitor paroxetine led to higher maximal concentrations and total exposures of LSD (geometric mean ratios of 1.4 and 1.5, respectively) indicating relevant involvement of CYP2D6 in its metabolism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The extent of this inhibition was nominally highest in genetic CYP2D6 normal metabolizers and lowest in poor metabolizers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The pharmacokinetic and pharmacodynamic interactions indicate that no dose adjustment of LSD seems necessary in the presence of an SSRI that inhibits CYP2D6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For SSRIs that do not relevantly inhibit CYP2D6, a dose increase of LSD might be appropriate, but due to lacking data and potential other pharmacokinetic interactions with these compounds, no definitive dose recommendation can be made.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other CYP2D6 inhibitors
“A similar or substantial increase in plasma LSD concentrations could be expected when patients who are on antidepressants that inhibit CYP2D6 (e.g., fluoxetine, paroxetine, duloxetine, and bupropion) and are treated with LSD-assisted therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This interaction warrants further study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consideration should also be given to discontinuing CYP2D6 inhibitors and allowing sufficient time for the enzyme to regenerate (up to 2 weeks) before LSD is used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Alternatively, in the presence of CYP2D6 inhibitors, the dose of LSD should be reduced, based on the present findings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MDMA co-administration
“MDMA slightly altered the pharmacokinetics of LSD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The plasma LSD elimination half-life was longer in the LSD + MDMA condition (5.2 h) compared with LSD alone (3.9 h; T = 5.00; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, MDMA and LSD primarily interact pharmacokinetically and not pharmacodynamically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MDMA is a strong inhibitor of CYP2D6, turning any CYP2D6 extensive or rapid metabolizer into a poor metabolizer within approximately 2 h” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ketanserin given after LSD
“Ketanserin reversed the acute response to LSD, thereby significantly reducing the duration of subjective effects from 8.5 hours with placebo to 3.5 hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ketanserin did not alter the pharmacokinetics of LSD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ketanserin can effectively be used as a planned or rescue option to shorten and attenuate the LSD experience in humans in research and LSD-assisted therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ketanserin, olanzapine, and lorazepam as rescue medications: registered study
Enzyme induction and inhibition in vitro
“Enzyme induction with rifampicin distinctly increased the formation of both metabolites, whereas treatment with omeprazole only slightly increased formation of nor-LSD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Genetic polymorphisms and drug interactions could therefore influence pharmacokinetics and pharmacodynamics of LSD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Drug-drug interaction studies in humans are required to further assess the clinical relevance of these findings.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote